StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Analysts at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a report issued on Tuesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target on the stock.

Lipocine Stock Up 2.1 %

Shares of NASDAQ LPCN opened at $4.90 on Tuesday. The stock has a market capitalization of $26.22 million, a price-to-earnings ratio of -6.45 and a beta of 1.24. The firm has a 50-day moving average price of $5.14 and a 200 day moving average price of $5.41. Lipocine has a 52 week low of $2.44 and a 52 week high of $11.79.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Equities research analysts expect that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in shares of Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent SEC filing. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.